On the other hand, EVs present in liquid biopsies, such as serum, plasma, CSF, and pleural effusions, offer a crucial and untapped opportunity for the development of non-invasive biomarkers that can revolutionize the diagnosis, prognosis, and therapy monitoring not just for EGFR-dependent tumours, but also for a wider range of cancers and diseases. The gene discussed is EGFR; the disease is cancer.